Business Context and Reporting Period
This Form 8-K Current Report was filed by Trail One, Inc. (not Citius Pharmaceuticals, Inc.) on May 24, 2013. The filing reports a change in control and leadership effective on the Closing Date of May 24, 2013.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The only financial data disclosed relates to the change in control transaction:
- Transaction Consideration: $340,000 aggregate.
- Per Share Price: Approximately $0.034 per share.
- Adjustment: The consideration was reduced by the amount of all liabilities of the Registrant as of the Closing Date.
- Shares Transferred: 10,000,000 shares (approximately 55.6% of issued and outstanding common stock).
Material Changes
The filing details a significant change in ownership and corporate governance:
- Change in Control: Ralph Montrone (Selling Stockholder) sold 10,000,000 shares to Mohammad Omar Rahman.
- Leadership Transition: Mohammad Omar Rahman was appointed Chief Executive Officer and elected as a director. Ralph Montrone resigned as an officer and agreed to resign as a director.
- Corporate Structure: Upon the resignation of the Selling Stockholder, Mr. Rahman became the sole officer and director of the Registrant.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, financial outlook, or specific risk factors beyond the standard disclosure of the transaction. Regarding compensation, Mr. Rahman has no agreement to receive compensation for his services as CEO or director, other than the reimbursement of reasonable expenses. There are no related party transactions requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the exact amount of liabilities assumed by the buyer, as the $340,000 consideration was net of these liabilities.
- Confirm the current status of the company's operations and whether the change in control has altered the business strategy.
- Review subsequent filings to determine if Mr. Rahman has entered into a formal compensation agreement since becoming the sole officer and director.
- Check for any undisclosed liabilities or contingent obligations not reflected in the transaction adjustment.